Trial reportAddiction (Abingdon, England)2026
Secondary analysis of a combined harm-reduction treatment and extended-release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth.
Trial report in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimsIn a prior randomized clinical trial (RCT), combined pharmacobehavioral harm-reduction treatment improved alcohol outcomes and physical health-related quality of life (PH-QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.
designSecondary study of a four-arm RCT.
settingCommunity settings serving people experiencing homelessness in the US Pacific Northwest.
participantsAdults aged 21-65 (N = 308) with alcohol use disorder (AUD) who experienced past-year homelessness.
interventionIn the parent RCT, participants were randomized to brief behavioral harm-reduction treatment for AUD + extended-release naltrexone (HaRT-A + XR-NTX); HaRT-A + placebo; HaRT-A alone, or services-as-usual control. MEASUREMENT: We tested whether baseline outcomes, trial inclusion, data missingness, treatment adherence, side effects, and treatment effects on alcohol frequency, quantity, alcohol-related harm, urinary ethyl glucuronide, and PH-QoL differed by race, ethnicity, and sex assigned at birth.
findingsRace, ethnicity and sex assigned at birth were not associated with differential trial inclusion, missingness, treatment adherence or side effects with one exception: the Multiracial/other people of color (POC) group attended fewer HaRT-A sessions than the white group (odds ratio [OR] = 0.49, p = 0.03, 95% confidence interval [CI] [0.25, 0.95]). There were no statistically significant moderators of the behavioral HaRT-A effect; however, Multiracial/other POC race (B = -3.34, p = 0.03, 95% CI [-6.35, -0.34]) and sex assigned at birth (B = 2.43, p = 0.04, 95% CI [0.14, 4.73]) moderated the XR-NTX versus placebo effect on one variable: PH-QoL. Simple slope analysis indicated the Multiracial/other POC group who received placebo showed improvement on PH-QoL (dy/dx = 2.61, p = 0.003, 95% CI [0.91, 4.31]); the XR-NTX group did not (dy/dx = -0.22, p = 0.79, 95% CI [-1.90, 1.45]). Among XR-NTX recipients, the female group (dy/dx = 2.89, p < 0.001, 95% CI [1.53, 4.25]) showed faster improvement rates than the male group (dy/dx = 1.19, p = 0.02, 95% CI [0.23, 2.16]) on PH-QoL.
conclusionRace, ethnicity and sex assigned at birth were largely not associated with trial inclusion, data missingness, treatment adherence, side effects, or outcomes in a combined harm-reduction treatment and extended-release naltrexone randomised clinical trial for alcohol use disorder (AUD). Although Multiracial/other people of color (POC) participants attended fewer brief behavioral harm-reduction treatment for AUD sessions, they did not differ from white participants on alcohol and physical health-related quality of life outcomes. Among participants receiving extended-release naltrexone (XR-NTX), women showed greater improvement than men on physical health-related quality of life. Compared with white participants, Multiracial/other POC participants who received XR-NTX showed less improvement than those who received placebo. Given their post hoc nature and limited power, findings are hypothesis-generating. They suggest the equitable utility of behavioral harm-reduction treatment and the importance of assessing sociodemographic differences in AUD treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.